AKRO vs. AVGO

In the year-to-date period, AKRO achieves a 78.47% return, which is significantly higher than AVGO's 4.73% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Akero Therapeutics, Inc. (AKRO) and Broadcom Inc. (AVGO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current AKRO Sharpe Ratio is 1.52, which is comparable to the AVGO Sharpe Ratio of 1.27. The chart below compares the historical Sharpe Ratios of AKRO and AVGO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

AKRO has not paid dividends to shareholders, while AVGO's dividend yield for the trailing twelve months is around 0.92%.

The maximum AKRO drawdown since its inception was -79.99%, which is greater than AVGO's maximum drawdown of -48.30%. Use the drawdown chart below to compare losses from any high point for AKRO and AVGO.

Akero Therapeutics, Inc. (AKRO) has a higher volatility of 28.17% compared to Broadcom Inc. (AVGO) at 9.20%. This indicates that AKRO's price experiences larger fluctuations and is considered to be riskier than AVGO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Akero Therapeutics, Inc. and Broadcom Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.